Pharmaceutical Industry Websites

The following sites are sponsored by the manufacturers of these pharmaceutical agents:

Treat to Target # 2 – Fragility Fracture

January 31, 2018 @ 8:23 pm
posted by Dr Ginther

Treat to Target means aiming for NO NEW FRACTURES.  As discussed last time, the original target was to maintain Bone Mineral Density (BMD) at the level first tested.  25 years ago that was amended to be a T-score of -2.4 or higher, since “osteoporosis the test result” was set at -2.5.

But what if you already have fractured?  Clinical Osteoporosis the diagnosis is a T-score of -1.5 plus a “Fragility Fracture” acquired in any fall from standing height, even on ice.  That is because for the first year after a fracture your risk is 5 times normal. Your risk decreases to 2 times normal after 5 years, but always is higher after a fragility fracture.

If your Fragility Fracture was a Hip Fracture, you have Clinical Osteoporosis regardless of DXA BMD and T-score.  You are at high risk of future fracture, especially of the other hip.  You should start treatment to prevent a new fracture.  At the very least you need to optimize calcium, vitamin D3, protein, and multiple vitamins & minerals intake.

If you also need a pharmaceutical, it should be one which can raise your T-score above -2.5 if you have no fractures, and above -1.5 if you already have a fracture.  That usually means considering an anabolic.  Your goal is NO NEW FRACTURES.

FRAX next time.

Jay Ginther, MD

Leave a Reply